Effect of sorafenib maintenance on Epstein-Barr virus and cytomegalovirus infections in patients with FLT3-ITD AML undergoing allogeneic hematopoietic stem cell transplantation: a secondary analysis of a randomized clinical trial

Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation

(2021) Li Xuan et al.   Journal of Hematology & Oncology

Emerging agents and regimens for AML

(2021) Hongtao Liu   Journal of Hematology & Oncology

Immune control of cytomegalovirus reactivation in stem cell transplantation

(2021) Mariapia A Degli-Esposti et al.   BLOOD

Epstein-Barr virus-associated post-transplant lymphoproliferative disease during dasatinib treatment occurred 10 years after umbilical cord blood transplantation

(2021) Akiko Yamada et al.   JOURNAL OF INFECTION AND CHEMOTHERAPY

FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions

(2020) Ahmad I. Antar et al.   LEUKEMIA

Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

(2020) Ali Bazarbachi et al.   HAEMATOLOGICA

Haploidentical versus HLA-matched sibling transplantation for refractory acute leukemia undergoing sequential intensified conditioning followed by DLI: an analysis from two prospective data

(2020) Sijian Yu et al.   Journal of Hematology & Oncology

Infectious Complications of Tyrosine Kinase Inhibitors in Hematological Malignancies

(2020) Andrew Kin et al.   INFECTIOUS DISEASE CLINICS OF NORTH AMERICA

Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3–Internal Tandem Duplication Mutation (SORMAIN)

(2020) Andreas Burchert et al.   JOURNAL OF CLINICAL ONCOLOGY

Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial

(2020) Li Xuan et al.   LANCET ONCOLOGY

Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML

(2020) Musa Yilmaz et al.   Journal of Hematology & Oncology

Risk Factors and Predictive Scoring System For Post-Transplant Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation

(2019) Ayumi Fujimoto et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Epstein-Barr virus-related post-transplant lymphoproliferative disease (EBV-PTLD) in the setting of allogeneic stem cell transplantation: a comprehensive review from pathogenesis to forthcoming treatment modalities

(2019) Rama Al Hamed et al.   BONE MARROW TRANSPLANTATION

Epstein-Barr virus-associated lymphoproliferative disease during imatinib mesylate treatment for chronic myeloid leukemia

(2019) Junko Yamaguchi et al.   HAEMATOLOGICA

Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7)

(2019) Per Ljungman et al.   LANCET INFECTIOUS DISEASES

Two dose levels of rabbit antithymocyte globulin as graft-versus-host disease prophylaxis in haploidentical stem cell transplantation: a multicenter randomized study

(2019) Ren Lin et al.   BMC Medicine

Viral infections and immune reconstitution interaction after pediatric allogenic hematopoietic stem cell transplantation

(2019) Adam Alexandersson et al.   Infectious Diseases

Immunomodulatory Effects of Tyrosine Kinase Inhibitor In Vitro and In Vivo Study

(2018) Elena Marinelli Busilacchi et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Repurposing nilotinib for cytomegalovirus infection prophylaxis after allogeneic hematopoietic stem cell transplantation: a single-arm, phase 2 trial

(2018) Chien-Ting Lin et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Effect of sorafenib on the outcomes of patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation

(2018) Li Xuan et al.   CANCER

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors)

(2018) M. Reinwald et al.   CLINICAL MICROBIOLOGY AND INFECTION

Infections in patients on BCR-ABL tyrosine kinase inhibitor therapy: cases and review of the literature

(2018) Bettina M. Knoll et al.   INFECTION

Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells

(2018) Nimitha R Mathew et al.   NATURE MEDICINE

Practical recommendations for reporting Fine-Gray model analyses for competing risk data

(2017) Peter C. Austin et al.   STATISTICS IN MEDICINE

Dasatinib-Induced Colitis after Allogeneic Stem Cell Transplantation for Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia

(2016) Ibrahim Aldoss et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Haematopoietic cell transplantation with and without sorafenib maintenance for patients withFLT3-ITD acute myeloid leukaemia in first complete remission

(2016) Andrew M. Brunner et al.   BRITISH JOURNAL OF HAEMATOLOGY

Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines

(2016) J. Styczynski et al.   HAEMATOLOGICA

Genomic Classification and Prognosis in Acute Myeloid Leukemia

(2016) Elli Papaemmanuil et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dasatinib-Induced CMV Hepatitis in an Immunocompetent Patient: A Rare Complication of a Common Drug

(2016) Fidencio Davalos et al.   Translational Oncology

Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines

(2016) J. Styczynski et al.   HAEMATOLOGICA

Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation

(2015) S. G. Holtan et al.   BLOOD

ROS-mediated JNK/p38-MAPK activation regulates Bax translocation in Sorafenib-induced apoptosis of EBV-transformed B cells

(2014) GA BIN PARK et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies

(2012) Li Xuan et al.   Journal of Hematology & Oncology

The multi-targeted kinase inhibitor sorafenib inhibits human cytomegalovirus replication

(2010) Martin Michaelis et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT

(2008) P Ljungman et al.   BONE MARROW TRANSPLANTATION

Platelet-derived growth factor-α receptor activation is required for human cytomegalovirus infection

(2008) Liliana Soroceanu et al.   NATURE